Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, reported a net loss of $219.0 million for the year ended December 31, 2025, compared to a net loss of $169.0 million for the previous year. The company's collaboration revenue increased to $72.6 million from $35.3 million in 2024, primarily driven by revenue from Novartis and Bayer collaborations due to termination notices. Research and development expenses also increased significantly, reaching $240.3 million, up from $173.0 million in the prior year, reflecting increased clinical program expenses for zelenectide pevedotin and the advancement of the Bicycle radioligand molecule pipeline. General and administrative expenses rose to $79.4 million from $72.2 million, mainly due to higher personnel-related costs and share-based compensation.
The company's strategic focus remains on oncology, particularly its Bicycle Drug Conjugate (BDC) and Bicycle Radioconjugate (BRC) programs. Nuzefatide pevedotin, a BDC targeting EphA2, is currently in Phase I/II and Phase II clinical trials. BT1702, a BRC targeting MT1-MMP, is undergoing IND-enabling activities. Zelenectide pevedotin, a BDC targeting Nectin-4, is being evaluated in a Phase I/II clinical trial and a Phase II/III registrational trial, although the latter is planned to be converted to a randomized Phase II trial. BT7480, a Bicycle TICA molecule, is being evaluated in a Phase I/II clinical trial, but the company intends to explore partnership opportunities for its future development.
In March 2026, Bicycle Therapeutics announced a strategic reprioritization of its clinical portfolio, focusing on next-generation therapeutics like nuzefatide pevedotin and BRC molecules. This decision led to the deprioritization of internal development for zelenectide pevedotin and the discontinuation of certain Phase I/II clinical trials. As part of this reprioritization, the company is implementing a workforce reduction of approximately 30%, expected to reduce annual operating expenses by about 50%. The company's cash and cash equivalents stood at $628.1 million as of December 31, 2025, which it believes will fund operations for at least the next 12 months.
Bicycle Therapeutics is also engaged in collaborations with biopharmaceutical companies, including Ionis and Bayer, to develop therapies in areas beyond oncology. ION826 (AZD4063), an investigational medicine incorporating a TfR1 Bicycle molecule under the Ionis collaboration agreement, entered Phase I development in December 2025. The company's intellectual property portfolio includes numerous patent families directed to novel scaffolds, linkers, payloads, platform technology, bicyclic peptides, and related conjugates. As of December 31, 2025, the company had 288 full-time or part-time employees, with a significant portion dedicated to research and development activities.
About BICYCLE THERAPEUTICS plc
Bicycle Therapeutics plc is a clinical-stage pharmaceutical company developing fully synthetic, constrained peptide-based therapeutics called Bicycle® molecules. These molecules combine biologic-like target specificity with small molecule pharmacokinetics and manufacturing advantages. The company’s core products include Bicycle Toxin Conjugates (BTCs), Tumor-Targeted Immune Cell Agonists (TICAs), and Radionuclide Conjugates (BRCs), primarily targeting oncology indications. Its proprietary phage display platform enables rapid discovery of candidates for diverse diseases, focusing on improved tumor penetration, selectivity, and safety.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.